These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 2642787)
1. Reduction of virus load in blood donations by screening methods. Kühnl P; Seidl S; Böhm BO Curr Stud Hematol Blood Transfus; 1989; (56):9-22. PubMed ID: 2642787 [No Abstract] [Full Text] [Related]
2. Inactivation of viruses in blood and plasma products. Suomela H Transfus Med Rev; 1993 Jan; 7(1):42-57. PubMed ID: 8431658 [No Abstract] [Full Text] [Related]
3. Approaches to the reduction of viral infectivity in cellular blood components and single donor plasma. Wagner SJ; Friedman LI; Dodd RY Transfus Med Rev; 1991 Jan; 5(1):18-32. PubMed ID: 1802274 [No Abstract] [Full Text] [Related]
4. Overview of viruses relevant to blood transfusion. Schilt U Curr Stud Hematol Blood Transfus; 1989; (56):1-8. PubMed ID: 2642782 [No Abstract] [Full Text] [Related]
5. Reducing the residual risk of transfusion-transmitted viruses: mini-pool or single-donation NAT? Roth WK; Seifried E Transfusion; 2001 Jun; 41(6):845-7. PubMed ID: 11399831 [No Abstract] [Full Text] [Related]
6. The significance of the blood-borne viruses: blood banking and transfusion medicine. Sherwood WC Dev Biol Stand; 1993; 81():25-33. PubMed ID: 8174810 [TBL] [Abstract][Full Text] [Related]
8. [Viral safety measures of plasma for transfusion and applicability in Spain]. Pereira A Med Clin (Barc); 2007 Oct; 129(12):458-68. PubMed ID: 17953912 [No Abstract] [Full Text] [Related]
9. Safety of human albumin as a constituent of biologic therapeutic products. McClelland DB Transfusion; 1998 Jul; 38(7):690-9. PubMed ID: 9683109 [No Abstract] [Full Text] [Related]
11. The role of leukodepletion in the control of transfusion-transmitted disease. Goldman M; Delage G Transfus Med Rev; 1995 Jan; 9(1):9-19. PubMed ID: 7719040 [No Abstract] [Full Text] [Related]
12. Photoinactivation of viruses and cells for medical applications. Corash L; Hanson CV Blood Cells; 1992; 18(1):3-5. PubMed ID: 1617191 [No Abstract] [Full Text] [Related]
14. At what stage should virus inactivation be carried out? Dorner F; Barrett PN; Eibl J Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796 [TBL] [Abstract][Full Text] [Related]
15. Further enhancement of the safety of human plasma derivatives. Lamb C Transfusion; 2002 Aug; 42(8):973-4. PubMed ID: 12385405 [No Abstract] [Full Text] [Related]
16. Genomic screening for blood-borne viruses in transfusion settings. Lee HH; Allain JP Vox Sang; 1998; 74 Suppl 2():119-23. PubMed ID: 9704433 [No Abstract] [Full Text] [Related]
17. Kill and cure. The hope and reality of virus inactivation. Prowse C Vox Sang; 1994; 67 Suppl 3():191-6. PubMed ID: 7975491 [No Abstract] [Full Text] [Related]
18. Polymerase chain reaction and transfusion microbiology. Barbara JA; Garson JA Vox Sang; 1993; 64(2):73-81. PubMed ID: 8384393 [TBL] [Abstract][Full Text] [Related]
20. Can we improve the management of blood donors with nonspecific reactivity in viral screening and confirmatory assays? Kiely P; Wood E Transfus Med Rev; 2005 Jan; 19(1):58-65. PubMed ID: 15830328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]